Abstract
Objective Clinical assessments of individuals with Cognitive-Motor Dissociation (CMD) following brain injury are challenging and prone to errors. This prompts investigation of objective, movement-independent neurophysiological markers using electroencephalography (EEG)-based Brain-Computer Interface (BCI) technology. The current pilot study involving adults with prolonged disorders of consciousness (PDoC) investigated the combination of Motor-Imagery BCI (MI-BCI) training and auditory evoked Event Related Potentials (ERPs) using an oddball paradigm to produce complementary biomarkers to improve evaluation of awareness in PDoC.
Approach EEG data (16 channels) were collected from participants with Unresponsive Wakefulness Syndrome (UWS, n = 2), Minimally Conscious State (MCS, n = 3), and Locked-In Syndrome (LIS, n = 4). The MI-BCI involved assessing sensorimotor rhythm modulation, motor-imagery training with and without auditory feedback, and motor-imagery responses to closed questions over 12 sessions each lasting ∼1hour. The oddball protocol was also deployed in 2-3 of those sessions, with ∼10 days between first and last, featuring auditory stimuli, comprising two 5-minute sets of standard, deviant beeps plus novel sounds, in a structured ratio. We expected those with the lowest levels of awareness would have reduced ERP components, with highest latencies to peak, as well as lowest accuracy in the motor imagery BCI protocol – and that trends across these metrics would be observed across the three patient groups based on their clinical diagnoses.
Main results Significant differences in mean N1 component latencies and mean MI Decoding Accuracies (DA, for significant runs) occurred between groups – with shorter N1 latencies for the LIS and MCS groups than for the UWS group (LIS vs. UWS and MCS vs. UWS, p < 0.001), and higher DA for the LIS group compared to MCS and UWS (p < 0.001). Mean DA were found to have a significant negative correlation with mean N1 latencies (two-tailed, p = 0.017).
Significance The results indicate that neurophysiological markers from the concomitant application of an MI-BCI and auditory-oddball paradigm can augment standard clinical assessments by providing objective measures that produce robust evidence of awareness in people with PDoC.
Competing Interest Statement
Damien Coyle is Founder and CEO of NeuroCONCISE Ltd, a neurotechnology company.
Clinical Trial
NCT03827187
Clinical Protocols
https://clinicaltrials.gov/study/NCT03827187
Funding Statement
This research has been supported by access to the Tier 2 High Performance Computing resources provided by the Northern Ireland High Performance Computing (NI-HPC) facility funded by the UK EPSRC under Grant number EP/T022175 and the UKRI Turing AI Fellowship 2021-2025 funded by the EPSRC under Grant number EP/V025724/1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this research was obtained from both the United Kingdom (UK) National Health Service (NHS) Scotland Research Ethics Committee (Reference, 18/SS/0064) and the NHS Health Research Authority (HRA) and Health and Care Research Wales (HCRW) (Reference, 18/WA/0186). The study was conducted in full accordance with the principles outlined in the Declaration of Helsinki, Good Clinical Practice guidelines, and all applicable local regulatory requirements. Participants provided informed consent prior to participation. This research is part of a larger-scale trial, titled, Awareness Detection and Communication in Disorders of Consciousness, registered with clinicaltrials.gov: https://clinicaltrials.gov/study/NCT03827187
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data supporting the findings of this study are available from the corresponding author upon reasonable request.
